• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Bolt Biotherapeutics Inc.

    3/24/25 4:31:37 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLT alert in real time by email
    S-8 1 2025_s-8_evergreen.htm S-8 S-8

    As filed with the U.S. Securities and Exchange Commission on March 24, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    BOLT BIOTHERAPEUTICS, INC.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware

    47-2804636

    (State or other jurisdiction of

    Incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    900 Chesapeake Drive

    Redwood City, California 94063

    (650) 665-9295

    (Address of principal executive offices) (Zip code)

    Bolt Biotherapeutics, Inc. 2021 Equity Incentive Plan

    Bolt Biotherapeutics, Inc. 2021 Employee Stock Purchase Plan

    (Full titles of the plans)

    William P. Quinn

    Chief Executive Officer

    Bolt Biotherapeutics, Inc.

    900 Chesapeake Drive

    Redwood City, California 94063

    (650) 665-9295

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

    Copy to:

    John T. McKenna

    Cooley LLP

    3175 Hanover Street

    Palo Alto, CA 94304

    (650) 843-5000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒


    EXPLANATORY NOTE

    Bolt Biotherapeutics, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering an additional (a) 1,916,984 shares of its common stock, par value $0.00001 per share (the “Common Stock”), issuable to eligible persons under the 2021 Equity Incentive Plan, which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s registration statement on Form S-8s filed on February 5, 2021 (File No. 333-252815), March 30, 2022 (File No. 333-263987), March 29, 2023 (File No. 333-270938), and March 21, 2024 (File No. 333-278141), (the “Prior Form S-8s”), and (b) 383,396 shares of Common Stock issuable to eligible persons under the 2021 Employee Stock Purchase Plan, which Common Stock is in addition to the shares of Common Stock registered on the Prior Form S-8s.

    PART II

    ITEM 3.

    INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

    Pursuant to General Instruction E to Form S-8, the contents of the Prior Form S-8s are incorporated by reference herein.

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed on March 24, 2025, which contains audited financial statements for the Registrant’s latest fiscal year.

    (b) The description of the Common Stock which is contained in a registration statement on Form 8-A filed on February 2, 2021 (File No. 001-39988) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

    (c) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 8.

    EXHIBITS

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Incorporated by Reference

     

     

    Exhibit
    Number

     

    Description

     

    Schedule
    Form

     

    File Number

     

    Exhibit

     

    Filing Date

     

     

     

     

     

     

    4.1

     

    Amended and Restated Certificate of Incorporation of the Registrant.

     

    8-K

     

    001-39988

     

    3.1

     

    2/9/2021

     

     

     

     

     

     

    4.2

     

    Amended and Restated Bylaws of the Registrant.

     

    S-1

     

    333-252136

     

    3.4

     

    1/15/2021

     

     

     

     

     

     

    4.3

     

    Form of common stock certificate of the Registrant.

     

    S-1

     

    333-252136

     

    4.1

     

    1/15/2021

     

     

     

     

     

     

    5.1*

     

    Opinion of Cooley LLP.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.1*

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.2*

     

    Consent of Cooley LLP (included in Exhibit 5.1).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    24.1*

     

    Power of Attorney (see signature page hereto).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.1

     

    2021 Equity Incentive Plan.

     

    S-1/A

     

    333-252136

     

    10.4

     

    2/1/2021

     

     

     

     

     

     

    99.2

     

    2021 Employee Stock Purchase Plan.

     

    S-1/A

     

    333-252136

     

    10.7

     

    2/1/2021

     

     

     

     

     

     

    107*

     

    Filing Fee Table.

     

     

     

     

     

     

     

     

     

    *

    Filed herewith

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on March 24, 2025.

     

     

     

    BOLT BIOTHERAPEUTICS, INC.

     

     

    By:

    /s/ William P. Quinn

     

    William P. Quinn

     

    President, Chief Executive Officer and Chief Financial Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints William P. Quinn and Sarah Nemec, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

    Signature

    Title

    Date

     

     

     

    /s/ William P. Quinn

    President, Chief Executive Officer and Chief Financial Officer

    March 24, 2025

    William P. Quinn

    (Principal Executive and Financial Officer)

     

     

     

     

    /s/ Sarah Nemec

    Senior Vice President, Finance

    March 24, 2025

    Sarah Nemec

    (Principal Accounting Officer)

     

     

     

     

    /s/ Brian O’Callaghan

     

    Chairman

     

    March 24, 2025

    Brian O’Callaghan

     

     

     

     

     

     

     

     

     

    /s/ Laura Berner

    Director

    March 24, 2025

    Laura Berner

     

     

     

     

     

    /s/ Jakob Dupont, M.D.

    Director

    March 24, 2025

    Jakob Dupont, M.D.

     

     

     

     

     

     

     

     

    /s/ Kathleen LaPorte

    Director

    March 24, 2025

    Kathleen LaPorte

     

     

     

     

     

     

     

     

     

     

    /s/ Nicole Onetto, M.D.

     

    Director

     

    March 24, 2025

    Nicole Onetto, M.D.

     

     

     

     

     

     

     

     


    Get the next $BOLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BOLT

    DatePrice TargetRatingAnalyst
    1/6/2022$45.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2022Overweight → Equal-Weight
    Morgan Stanley
    11/10/2021$35.00 → $33.00Outperform
    SVB Leerink
    8/16/2021$34.00 → $35.00Outperform
    SVB Leerink
    More analyst ratings

    $BOLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

      Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalat

      5/8/25 8:00:00 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

      CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced preclinical results from its next-generation Boltbody™ ISACs targeting CEACAM5 and PD-L1 at the American Association for Cancer Research (AACR) Annual Meeting. "We are encouraged by these early results from our next-generation Boltbody™ ISACs targeting CEA a

      4/30/25 4:05:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

      BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed signs of anti-tumor activity, including an unconfirmed partial response, stable disease ≥ 12 weeks in 3/3 non-small cell lung cancer patients and in 2/3 patients at the highest dose Bolt is running a partnering process to advance development of BDC-3042 REDWOOD CITY, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treat

      4/25/25 1:00:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Dupont Jakob

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 9:28:46 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Yonehiro Grant

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:41:01 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Senior VP, Finance and PAO Nemec Sarah bought $2,835 worth of shares (5,000 units at $0.57), decreasing direct ownership by 2% to 13,863 units (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:40:30 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc.

      SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

      11/14/24 4:19:06 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

      SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

      2/14/24 4:57:08 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

      SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

      2/14/24 4:00:25 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Financials

    Live finance-specific insights

    See more

    $BOLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BOLT
    SEC Filings

    See more

    $BOLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

      Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalat

      5/8/25 8:00:00 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

      Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Development to oversee all clinical activities; Edith Perez moving to an advisory roleCash balance of $112.8 million now expected to fund the Company into second half 2026, including generation of clinic

      5/14/24 4:05:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

      Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference call and webcast today at 8:00 a.m. ET/5:00 a.m. PT REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the presentation of interim clinical data from the company's ongoing Phase 1/2 study of BDC-1001, the company's lead immune-stimulat

      12/6/21 6:00:00 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Senior VP, Finance and PAO Nemec Sarah bought $2,835 worth of shares (5,000 units at $0.57), decreasing direct ownership by 2% to 13,863 units (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:40:30 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO and CFO Quinn William P. bought $2,835 worth of shares (5,000 units at $0.57) (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      5/5/25 8:35:34 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Quinn William P. bought $11,241 worth of shares (11,829 units at $0.95), increasing direct ownership by 48% to 36,272 units (SEC Form 4)

      4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

      12/13/23 1:40:19 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Bolt Biotherapeutics Inc.

      DEF 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

      4/25/25 3:48:22 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

      4/16/25 5:22:57 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Bolt Biotherapeutics Inc.

      PRE 14A - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

      4/15/25 7:12:43 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $45.00 previously

      1/6/22 9:46:37 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics downgraded by Morgan Stanley

      Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight

      1/6/22 7:59:47 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Bolt Biotherapeutics with a new price target

      SVB Leerink reiterated coverage of Bolt Biotherapeutics with a rating of Outperform and set a new price target of $33.00 from $35.00 previously

      11/10/21 6:28:31 AM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BOLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Bolt Biotherapeutics Announces Changes to its Board of Directors

      REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair. "Ja

      9/4/24 4:05:00 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira Appoints Frank D. Lee as Chief Executive Officer

      -- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r

      12/21/23 7:30:00 AM ET
      $BOLT
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

      REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. "Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience," said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. "As we continue to advance our immuno-oncology pipeline programs in the clinic, Laura brings important strategic perspective from leading and executing more than 50 transact

      12/14/22 4:43:15 PM ET
      $BOLT
      Biotechnology: Pharmaceutical Preparations
      Health Care